Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Loza

Showing results (71-80 of 111) with videos related to

Pageof 12
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|September 7, 2001
Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cellsL S Metelitsa, O V Naidenko, A Kant, et al.
American Journal of Clinical Pathology|April 7, 2023
PROSER: A Web-Based Peripheral Blood Smear Interpretation Support Tool Utilizing Electronic Health Record DataMark S Iscoe, Andrew J Loza, Donald Turbiville, et al.
RMD Open|May 20, 2021
Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trialsKristen Sweet, Qingxuan Song, Matthew J Loza, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|February 22, 2013
Nanotechnology in corneal neovascularization therapy--a reviewLilian Gonzalez, Raymond J Loza, Kyu-Yeon Han, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 14, 2018
A phase 2a study of toreforant, a histamine H<sub>4</sub> receptor antagonist, in eosinophilic asthmaAlexa P Kollmeier, Elliot S Barnathan, Christopher O'Brien, et al.
Annals of the American Thoracic Society|March 31, 2016
Longitudinally Stable, Clinically Defined Clusters of Patients with Asthma Independently Identified in the ADEPT and U-BIOPRED Asthma StudiesMatthew J Loza, Ian Adcock, Charles Auffray, et al.
Scientific Reports|October 3, 2024
Pharmacodynamic, prognostic, and predictive biomarkers in severe and critical COVID-19 patients treated with sirukumabKim Thys, Matthew J Loza, Linghua Lynn, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|April 24, 2018
Phase 2a, randomized, double-blind, placebo-controlled, multicentre, parallel-group study of an H<sub>4</sub> R-antagonist (JNJ-39758979) in adults with uncontrolled asthmaA P Kollmeier, A Greenspan, X L Xu, et al.
Therapeutic Advances in Musculoskeletal Disease|October 28, 2025
Safety, tolerability, and efficacy of the PD-1 agonist antibody JNJ-67484703 in adults with active rheumatoid arthritis: results of a multicenter, double-blind, placebo-controlled, randomized, multiple-dose phase Ib studyIrving T C Ling, Stanley J Marciniak, Stephen H Clarke, et al.
ERJ Open Research|December 28, 2023
Using an electronic diary and wristband accelerometer to detect exacerbations and activity levels in COPD: a feasibility studyLydia J Finney, Stefan Avey, Dexter Wiseman, et al.
Pageof 12

Showing results (71-80 of 111) with videos related to

Sort By:
Pageof 12
Journal of Immunology (Baltimore, Md. : 1950)|September 7, 2001
Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cellsL S Metelitsa, O V Naidenko, A Kant, et al.
American Journal of Clinical Pathology|April 7, 2023
PROSER: A Web-Based Peripheral Blood Smear Interpretation Support Tool Utilizing Electronic Health Record DataMark S Iscoe, Andrew J Loza, Donald Turbiville, et al.
RMD Open|May 20, 2021
Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trialsKristen Sweet, Qingxuan Song, Matthew J Loza, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|February 22, 2013
Nanotechnology in corneal neovascularization therapy--a reviewLilian Gonzalez, Raymond J Loza, Kyu-Yeon Han, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 14, 2018
A phase 2a study of toreforant, a histamine H<sub>4</sub> receptor antagonist, in eosinophilic asthmaAlexa P Kollmeier, Elliot S Barnathan, Christopher O'Brien, et al.
Annals of the American Thoracic Society|March 31, 2016
Longitudinally Stable, Clinically Defined Clusters of Patients with Asthma Independently Identified in the ADEPT and U-BIOPRED Asthma StudiesMatthew J Loza, Ian Adcock, Charles Auffray, et al.
Scientific Reports|October 3, 2024
Pharmacodynamic, prognostic, and predictive biomarkers in severe and critical COVID-19 patients treated with sirukumabKim Thys, Matthew J Loza, Linghua Lynn, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|April 24, 2018
Phase 2a, randomized, double-blind, placebo-controlled, multicentre, parallel-group study of an H<sub>4</sub> R-antagonist (JNJ-39758979) in adults with uncontrolled asthmaA P Kollmeier, A Greenspan, X L Xu, et al.
Therapeutic Advances in Musculoskeletal Disease|October 28, 2025
Safety, tolerability, and efficacy of the PD-1 agonist antibody JNJ-67484703 in adults with active rheumatoid arthritis: results of a multicenter, double-blind, placebo-controlled, randomized, multiple-dose phase Ib studyIrving T C Ling, Stanley J Marciniak, Stephen H Clarke, et al.
ERJ Open Research|December 28, 2023
Using an electronic diary and wristband accelerometer to detect exacerbations and activity levels in COPD: a feasibility studyLydia J Finney, Stefan Avey, Dexter Wiseman, et al.
Pageof 12